Pfizer and Nektar resolve Exubera contract
Pfizer and Nektar Therapeutics released a joint statement today announcing they have resolved all outstanding contractual issues related to Exubera and Nektar's Phase I next generation inhaled insulin (NGI) product.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.